https://assets.capyfin.com/instruments/678fdc13234e27009c5d583e.png avatar
Danaher
🇺🇸 NYSE:DHR
View Company
OverviewEarningsDividends
•
Dec 31, 2019

Danaher Q4 2019 Earnings Report

Danaher's Q4 2019 results reflected revenue growth and increased earnings per share.

Key Takeaways

Danaher Corporation reported a 5.5% increase in revenue to $4.9 billion for Q4 2019, with net earnings of $792.9 million, or $1.07 per diluted share. Non-GAAP adjusted diluted net earnings per share were $1.28, representing a 12.5% increase year-over-year. The company achieved 6.0% core revenue growth.

Revenue increased by 5.5% year-over-year to $4.9 billion.

Net earnings were $792.9 million, or $1.07 per diluted share.

Non-GAAP adjusted diluted net earnings per share were $1.28, a 12.5% increase year-over-year.

Core revenue growth was 6.0%.

Total Revenue
$4.87B
Previous year: $5.36B
-9.2%
EPS
$1.28
Previous year: $1.28
+0.0%
Core Sales Growth
6%
Gross Profit
$2.7B
Previous year: $2.96B
-8.5%
Cash and Equivalents
$19.9B
Previous year: $788M
+2427.6%
Free Cash Flow
$994M
Previous year: $1.02B
-2.8%
Total Assets
$62.1B
Previous year: $47.8B
+29.8%

Danaher

Danaher

Danaher Revenue by Segment

Forward Guidance

The Company anticipates for the first quarter 2020, diluted net earnings per share will be in the range of $0.78 to $0.81 and non-GAAP adjusted diluted net earnings per share will be in the range of $1.06 to $1.09. For the full year 2020, the Company anticipates that diluted net earnings per share will be in the range of $3.96 to $4.06 and non-GAAP adjusted diluted net earnings per share will be $4.80 to $4.90, which assumes non-GAAP core revenue growth of approximately 5.0%.

Positive Outlook

  • Diluted net earnings per share for Q1 2020 are expected to be in the range of $0.78 to $0.81.
  • Non-GAAP adjusted diluted net earnings per share for Q1 2020 are expected to be in the range of $1.06 to $1.09.
  • Diluted net earnings per share for FY 2020 are anticipated to be in the range of $3.96 to $4.06.
  • Non-GAAP adjusted diluted net earnings per share for FY 2020 are expected to be $4.80 to $4.90.
  • FY 2020 guidance assumes non-GAAP core revenue growth of approximately 5.0%.

Challenges Ahead

  • Q1 and FY 2020 estimated results do not include the impact of earnings from the pending GE Biopharma acquisition.
  • Uncertainty of regulatory approvals with respect to the GE Biopharma acquisition and the timing or conditionality thereof.
  • Parties' ability to satisfy the acquisition agreement conditions and consummate the acquisition of GE Biopharma on the anticipated timetable and terms or at all.
  • Danaher's ability to successfully integrate GE Biopharma's operations and employees with Danaher's existing business.
  • Ability to realize anticipated financial, tax and operational synergies and benefits.

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Company Overview

Full financial data and analysis

View Danaher